HLA-matched allo-SCT after reduced intensity conditioning with fludarabineCY in patients with metastatic breast cancer

Bone Marrow Transplantation

Volumn 45, Issue 3, 2010, Pages 464-467

  Fleskens, A J H M ^a   Lalisang, R I ^a   Bos, G M J ^a   Van Gelder, M ^a   Jansen, R L H ^a   Schouten, H C ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Metastatic breast cancer; Phase II study; Reduced intensity transplants; RIST

Indexed keywords

CA 15-3 ANTIGEN; CYCLOPHOSPHAMIDE; FLUDARABINE;

ADULT; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DONOR LYMPHOCYTE INFUSION; FEMALE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HLA MATCHING; HUMAN; METASTASIS POTENTIAL; MORTALITY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; SIBLING;

ADULT; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS TUMOR EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; MIDDLE AGED; MYELOABLATIVE AGONISTS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; VIDARABINE;

EID: 77949425235     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2009.178     Document Type: Article

References (20)

1. Thomas E, Storb R, Clift RA, Fefer A, Johnson FL, Neiman PE et al., Bone-marrow transplantation (first of two parts). N Engl J Med 1975; 292: 832.
2. Thomas ED, Storb R, Clift RA, Fefer A, Johnson L, Neiman PE et al., Bone-marrow transplantation (second of two parts). N Engl J Med 1975; 292: 895.
3. Huugen D, Schouten HC, Bos GM. Advantages and limitations of (non-) myeloablative allogeneic stem cell transplantation. Neth J Med 2002; 60: 162-169.
4. Buffart TE, Janssen JJWM, Huijgens PC. Reduced-intensity conditioning regimens in malignant haematological diseases. Neth J Med 2005; 63: 43-51.
5. Mielcarek M, Martin PJ, Leisenring W, Flowers MED, Maloney DG, Sandmaier BM et al., Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756.
6. Couriel DR, Saliba RM, Giralt S, Khouri I, Andersson B, de Lima M et al., Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation. Biol Blood Marrow Transplant 2004; 10: 178-185.
7. Sorror ML, Maris MB, Storer B, Sandmaier BM, Diaconescu R, Flowers C et al., Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood 2004; 104: 961-968.
8. Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ et al., Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 2005; 105: 1810-1814.
9. Childs RW, Clave E, Tisdale J, Plante M, Hensel N, Barrett J. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 1999; 17: 2044.
10. Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang M-J et al., Allogeneic hematopoietic cell transplantation for metastatic breast cancer. Bone Marrow Transplant 2008; 41: 537-545.
11. Demirer T, Barkholt L, Blaise D, Pedrazzoli P, Aglietta M, Carella AM et al., Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors. Nature Clinical Practice Oncology 2008; 5: 256-267.
12. Storb R, Deeg H, Farewell V, Doney K, Appelbaum F, Beatty P et al., Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graftversus- host disease. Blood 1986; 68: 119-125.
13. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al., Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
14. Sullivan KM, Shulman HM, Storb R, Weiden PL, Witherspoon RP, McDonald GB et al., Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981; 57: 267.
15. Carella AM, Beltrami G, Corsetti MT, Nati S, Musto P, Scalzulli P et al., Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer. Lancet 2005; 366: 318-320.
16. Bishop MR, Fowler DH, Marchigiani D, Castro K, Kasten- Sportes C, Steinberg SM et al., Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol 2004; 22: 3886-3892.
17. Ueno NT, Cheng YC, Rondon G, Tannir NM, Gajewski JL, Couriel DR et al., Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 2003; 102: 3829.
18. Bregni M, Dodero A, Peccatori J, Pescarollo A, Bernardi M, Sassi I et al., Nonmyeloablative conditioning followed by hematopoietic cell allografting and donor lymphocyte infusions for patients with metastatic renal and breast cancer. Blood 2002; 99: 4234.
19. Seidman AD, O0Shaughnessy J, Misset J-L. Single-agent capecitabine: a reference treatment for taxane-pretreated metastatic breast cancer? Oncologist 2002; 7: 20-28.
20. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A et al., Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295: 2097.